Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 -- Clearmind Medicine Inc. , , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major... | May 22, 2023

Related Keywords

Israel ,Frankfurt ,Brandenburg ,Germany ,New York ,United States ,Tel Aviv ,Canada ,Canadian ,Adi Zuloff Shani ,Yale School Of Medicine ,Nasdaq ,Frankfurt Stock Exchange ,Canadian Securities Exchange ,Ethics Committee ,Yale School Of Medicine Department Psychiatry ,Medicine Inc ,Exchange Commission ,Clearmind Medicine Inc ,Mount Sinai West Icahn School Of Medicine ,Yale School ,Anahita Bassir Nia ,Assistant Professor ,Mount Sinai Beth Israel ,Mount Sinai West ,Icahn School ,Chief Executive Officer ,Bassir Nia ,Private Securities Litigation Reform Act ,Clearmind Medicine Inc Stock Exchange ,News ,Information ,Press Release ,El ,Bay ,023 ,Clearmind ,Medicine ,Biotech ,Company ,Ocused ,N ,Discovery ,End ,Development ,F ,Novel ,Herapeutics ,O ,Olve Cmnd Ca1850532047 ,